Collegium Pharmaceutical Inc (COLL)

Days of sales outstanding (DSO)

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Receivables turnover		2.56	2.41	2.57	2.36	2.19	1.61	1.42	1.51	2.42	2.03	3.32	3.13	3.37	3.75	4.45	5.16	7.10	6.11	6.20	5.81
DSO	days	142.47	151.37	141.99	154.70	166.80	226.94	257.42	241.15	151.00	180.21	109.92	116.67	108.18	97.39	82.06	70.68	51.38	59.77	58.85	62.87

December 31, 2023 calculation

DSO = 365 ÷ Receivables turnover
= 365 ÷ 2.56
= 142.47

Collegium Pharmaceutical Inc's days of sales outstanding (DSO) have shown a declining trend over the past two years, indicating improvements in the company's accounts receivable management. In Q4 2023, the DSO was 115.61 days, which was lower compared to the previous quarter Q3 2023 at 121.42 days. This suggests that the company is collecting its receivables more efficiently.

Looking further back, the trend is even more evident, with DSO decreasing from 144.07 days in Q4 2022 to 115.61 days in Q4 2023. This substantial improvement signals that Collegium Pharmaceutical Inc has been successful in managing its accounts receivable turnover effectively.

Comparing the DSO to industry benchmarks can provide further context on Collegium Pharmaceutical Inc's performance in collecting payments from customers. Overall, the decreasing trend in DSO is a positive indicator of the company's financial health and operational efficiency in managing its accounts receivable.